Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CORT Stock Summary
Top 10 Correlated ETFs
CORT
In the News
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow
Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript
Corcept Therapeutics Incorporated (CORT) Q4 2023 Earnings Call Transcript
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2023 financial results and provide a corporate update on February 15, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Corcept (CORT) Stock Rises on Upbeat Revenue Guidance for 2024
Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.
Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva
The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.
Corcept Therapeutics shares sink after losing patent infringement lawsuit against Teva
Corcept Therapeutics shares fell by more than a quarter on Tuesday morning after a court found against it in a patent infringement lawsuit filed against Teva Pharmaceuticals. A US District Court said Teva does not infringe any asserted claims of Corcept's US Patents 10,195,214 and 10,842,800, both of which concern methods of safely administering its flagship Korlym drug with drugs that are strong inhibitors of CYP3A4, an enzyme mainly found in the liver and the intestine.
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CORT Financial details
CORT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.51 | 2.85 | 2.91 | 3.47 | 4.32 | |
Net income per share | 0.77 | 0.85 | 0.89 | 0.87 | 0.95 | |
Operating cash flow per share | 1.11 | 1.22 | 1.33 | 1.04 | 1.14 | |
Free cash flow per share | 1.1 | 1.21 | 1.33 | 1.03 | 1.14 | |
Cash per share | 4.58 | 6.77 | 3.82 | 6.92 | 3.3 | |
Book value per share | 3.03 | 4.21 | 2.98 | 4.33 | 4.53 | |
Tangible book value per share | 3.03 | 4.21 | 2.98 | 4.33 | 4.53 | |
Share holders equity per share | 3.03 | 4.21 | 2.98 | 4.33 | 4.53 | |
Interest debt per share | 0.09 | 0.04 | 0.01 | 0.05 | 0 | |
Market cap | 1.48B | 3.25B | 2.49B | 2.36B | 3.63B | |
Enterprise value | 1.17B | 2.77B | 2.16B | 1.92B | 3.49B | |
P/E ratio | 15.71 | 30.65 | 22.17 | 23.22 | 34.19 | |
Price to sales ratio | 4.83 | 9.18 | 6.81 | 5.86 | 7.52 | |
POCF ratio | 10.87 | 21.38 | 14.86 | 19.57 | 28.57 | |
PFCF ratio | 10.96 | 21.55 | 14.9 | 19.64 | 28.6 | |
P/B Ratio | 3.99 | 6.21 | 6.64 | 4.69 | 7.16 | |
PTB ratio | 3.99 | 6.21 | 6.64 | 4.69 | 7.16 | |
EV to sales | 3.81 | 7.84 | 5.9 | 4.78 | 7.24 | |
Enterprise value over EBITDA | 10.47 | 21.64 | 17.34 | 17.04 | 31.87 | |
EV to operating cash flow | 8.58 | 18.26 | 12.86 | 15.96 | 27.5 | |
EV to free cash flow | 8.65 | 18.41 | 12.89 | 16.01 | 27.53 | |
Earnings yield | 0.06 | 0.03 | 0.05 | 0.04 | 0.03 | |
Free cash flow yield | 0.09 | 0.05 | 0.07 | 0.05 | 0.03 | |
Debt to equity | 0.01 | 0.01 | 0 | 0 | 0 | |
Debt to assets | 0.01 | 0.01 | 0 | 0 | 0 | |
Net debt to EBITDA | -2.79 | -3.7 | -2.69 | -3.87 | -1.23 | |
Current ratio | 8.57 | 49.67 | 55.21 | 6.11 | 4.39 | |
Interest coverage | 22.01 | 0 | 0 | 31.67 | 0 | |
Income quality | 1.45 | 1.43 | 1.49 | 1.19 | 1.2 | |
Dividend Yield | 0 | 0.01 | 0.01 | 0.01 | 0 | |
Payout ratio | 0.07 | 0.2 | 0.13 | 0.24 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.29 | 0.32 | 0.31 | 0.33 | 0.38 | |
Intangibles to total assets | -0.1 | -0.06 | -0.26 | 0 | 0 | |
Capex to operating cash flow | -0.01 | -0.01 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.5 | -0.55 | -0.15 | -0.14 | -0.06 | |
Stock based compensation to revenue | 0.1 | 0.09 | 0.12 | 0.11 | 0.1 | |
Graham number | 7.25 | 9 | 7.74 | 9.23 | 9.84 | |
ROIC | 0.24 | 0.19 | 0.3 | 0.19 | 0.18 | |
Return on tangible assets | 0.21 | 0.17 | 0.21 | 0.17 | 0.17 | |
Graham Net | 4.44 | 6.63 | 3.68 | 6.58 | 2.67 | |
Working capital | 311.52M | 513.69M | 374.48M | 417.12M | 354.13M | |
Tangible asset value | 410.53M | 559.53M | 488.08M | 501.84M | 506.71M | |
Net current asset value | 311.52M | 475.85M | 333.44M | 417.12M | 343.82M | |
Invested capital | 0.01 | 0.01 | 0 | 0 | 0 | |
Average receivables | 18.76M | 23.06M | 26.91M | 36.34M | 50.09M | |
Average payables | 7.9M | 9.05M | 8.73M | 9.44M | 14.69M | |
Average inventory | 16.82M | 19.28M | 19.55M | 17.49M | 12.38M | |
Days sales outstanding | 23.73 | 27.02 | 27.55 | 40.92 | 41.71 | |
Days payables outstanding | 499.82 | 690.11 | 477.45 | 811.74 | 979.72 | |
Days of inventory on hand | 1.15K | 1.38K | 1.24K | 1.15K | 435.34 | |
Receivables turnover | 15.38 | 13.51 | 13.25 | 8.92 | 8.75 | |
Payables turnover | 0.73 | 0.53 | 0.76 | 0.45 | 0.37 | |
Inventory turnover | 0.32 | 0.26 | 0.29 | 0.32 | 0.84 | |
ROE | 0.25 | 0.2 | 0.3 | 0.2 | 0.21 | |
Capex per share | -0.01 | -0.01 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.89 | 0.94 | 1.08 | 1.11 | 1.22 | |
Net income per share | 0.14 | 0.14 | 0.25 | 0.28 | 0.28 | |
Operating cash flow per share | 0.29 | 0.23 | 0.39 | 0.48 | 0.05 | |
Free cash flow per share | 0.29 | 0.23 | 0.39 | 0.48 | 0.05 | |
Cash per share | 6.89 | 5.58 | 3.32 | 3.2 | 3.31 | |
Book value per share | 4.31 | 4.69 | 3.85 | 4.16 | 4.56 | |
Tangible book value per share | 4.31 | 4.69 | 3.85 | 4.16 | 4.56 | |
Share holders equity per share | 4.31 | 4.69 | 3.85 | 4.16 | 4.56 | |
Interest debt per share | 0.03 | -0.02 | 0 | 0 | 0.03 | |
Market cap | 2.36B | 2.45B | 2.43B | 3.03B | 3.61B | |
Enterprise value | 1.93B | 1.98B | 2.26B | 2.92B | 3.47B | |
P/E ratio | 35.58 | 38.5 | 22.11 | 24.12 | 28.77 | |
Price to sales ratio | 22.93 | 23.15 | 20.68 | 24.49 | 26.65 | |
POCF ratio | 70.76 | 94.22 | 57.58 | 57.21 | 612.99 | |
PFCF ratio | 70.83 | 94.22 | 57.72 | 57.25 | 612.99 | |
P/B Ratio | 4.71 | 4.62 | 5.77 | 6.56 | 7.12 | |
PTB ratio | 4.71 | 4.62 | 5.77 | 6.56 | 7.12 | |
EV to sales | 18.7 | 18.75 | 19.22 | 23.59 | 25.65 | |
Enterprise value over EBITDA | 85.65 | 133.38 | 74.41 | 93 | 107.53 | |
EV to operating cash flow | 57.72 | 76.32 | 53.51 | 55.1 | 589.99 | |
EV to free cash flow | 57.77 | 76.32 | 53.64 | 55.14 | 589.99 | |
Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Free cash flow yield | 0.01 | 0.01 | 0.02 | 0.02 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | -19.36 | -31.27 | -5.66 | -3.56 | -4.19 | |
Current ratio | 6.11 | 20.95 | 4.65 | 3.54 | 4.39 | |
Interest coverage | 12.66 | -4.15 | 0 | 0 | 8.84 | |
Income quality | 2.01 | 1.63 | 1.54 | 1.69 | 0.19 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.08 | 0.11 | 0.02 | 0.16 | 0.04 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.36 | 0.39 | 0.37 | 0.37 | 0.4 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.04 | 0 | -0.12 | -0.22 | 0 | |
Stock based compensation to revenue | 0.1 | 0.11 | 0.1 | 0.1 | 0.1 | |
Graham number | 3.72 | 3.85 | 4.67 | 5.14 | 5.38 | |
ROIC | 0.03 | 0.02 | 0.06 | 0.06 | 0.05 | |
Return on tangible assets | 0.03 | 0.03 | 0.05 | 0.05 | 0.05 | |
Graham Net | 6.56 | 5.18 | 2.73 | 2.37 | 2.69 | |
Working capital | 417.12M | 502.96M | 339.53M | 309.65M | 354.13M | |
Tangible asset value | 501.84M | 529.58M | 421.61M | 461.68M | 506.71M | |
Net current asset value | 417.12M | 439.92M | 329.58M | 299.18M | 343.82M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 37.24M | 45.81M | 46.56M | 47.59M | 51.87M | |
Average payables | 10.08M | 11.6M | 9.6M | 12.34M | 17.05M | |
Average inventory | 11.54M | 16.8M | 11.74M | 7.21M | 7.62M | |
Days sales outstanding | 39.35 | 39.66 | 35.59 | 35.41 | 36.64 | |
Days payables outstanding | 728.27 | 728.31 | 456.06 | 914.22 | 834.12 | |
Days of inventory on hand | 1.04K | 1.08K | 395.39 | 411.05 | 370.64 | |
Receivables turnover | 2.29 | 2.27 | 2.53 | 2.54 | 2.46 | |
Payables turnover | 0.12 | 0.12 | 0.2 | 0.1 | 0.11 | |
Inventory turnover | 0.09 | 0.08 | 0.23 | 0.22 | 0.24 | |
ROE | 0.03 | 0.03 | 0.07 | 0.07 | 0.06 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CORT Frequently Asked Questions
What is Corcept Therapeutics Incorporated stock symbol ?
Corcept Therapeutics Incorporated is a US stock , located in Menlo park of Ca and trading under the symbol CORT
Is Corcept Therapeutics Incorporated buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $31.5. The lowest prediction is $30 and the highest is $33
What is CORT stock prediction ?
What is Corcept Therapeutics Incorporated stock quote today ?
Corcept Therapeutics Incorporated stock price is $25.32 today.
Is Corcept Therapeutics Incorporated stock public?
Yes, Corcept Therapeutics Incorporated is a publicly traded company.